 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...2021222324252627282930...132133» |
- fulvestrant / Generic mfg.
Efficacy of fulvestrant-based therapies in treating HR-positive, HER2-negative breast cancer with liver metastasis (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1244;
While novel fulvestrant-based combination therapies have been promising for MBC, similar survival benefits are not seen in those with liver metastasis. Liver metastasis proves to be aggressive and difficult to treat, and current therapies are insufficient.
- Piqray (alpelisib) / Novartis, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Histology-based survival outcomes in HR+/HER2- metastatic breast cancer treated with targeted therapies plus endocrine therapy based on HER2 expression (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1235;
Table 1. Progression-free Survival and Overall Survival in HR+/HER2- mBC patients treated with targeted therapies (TT) plus endocrine therapy (ET) In patients treated with TT + ET in all histologies (A), in IDC (B) and in ILC (C).
- Piqray (alpelisib) / Novartis
ctDNA as dynamic marker of response to fulvestrant and everolimus in CDK4/6 inhibitor-pretreated ER+ HER2- metastatic breast cancer patients: a prospective study (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1224;
P=N/A
The PFS observed under fulvestrant-everolimus in patients with PIK3CA-mutant mBC appears shorter than previouly reported with alpelisib in the BYLIEVE study. Results of ctDNA to monitor the individual response to therapy will be presented at the congress.
- Ibrance (palbociclib) / Pfizer
Real-world treatment duration of subsequent therapy after palbociclib (PAL) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) in Japan (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_978;
ET+targeted therapy and chemotherapy represent acceptable treatment options after PAL+ET. One-third of patients received CDK4/6i+ET after PAL+ET in Japanese clinical practice; however, further investigation is warranted to confirm that this treatment strategy is effective.
- Inhibition of FASN as a potential treatment of advanced endocrine therapy-resistant breast cancer (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_949;
Our preclinical data provide evidence that FASN inhibition by TVB-3166 presents a promising therapeutic strategy for treatment of endocrine-resistant breast cancer. Further clinical development of FASN inhibitors for endocrine resistant breast cancer should be considered.
- everolimus / Generic mfg.
A real-world evidence study of everolimus plus endocrine therapy beyond CDK4/6 inhibitors for HR+/HER2- advanced breast cancer (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_767;
Conclusions In our cohort, the use of everolimus plus ET in mBC patients previously treated with a CDK4/6 inhibitor showed a clinically significant benefit in terms of PFS, especially in patients without visceral metastasis, and no previous chemotherapy for advanced disease. In this real-world study, the toxicity profile of everolimus was manageable.
- everolimus / Generic mfg.
Patients’ selection of daily timing of oral intake of adjuvant hormonotherapy (HT) and everolimus (EVE) for high risk early breast cancer in the UCBG-UNIRAD phase III trial (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_522;
P3
Age and menopausal status were important determinants of patient-selected daily timing intakes of both EVE and HT, as well as HT types. These findings will be carefully considered in the analyses of possible EVE and HT timing effects on adverse events and efficacy of the current adjuvant regimens.
- camizestrant (AZD9833) / AstraZeneca
Combination of the next generation oral SERD camizestrant (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in a broad range of ER+ breast tumors (Stars at Night Ballroom 3&4) - Oct 10, 2022 - Abstract #SABCS2022SABCS_239;
To explore camizestrant combination potential as a backbone ET, camizestrant was partnered with either palbociclib or abemaciclib in CDK4/6 inhibitor (CDK4/6i) naïve and resistant in vitro and in vivo models...Camizestrant delivered enhanced efficacy when combined with mTORC1 inhibitor everolimus and AKT inhibitor capivasertib in CTC-174, an ESR1m and PI3KCAm tumor model...These preclinical data demonstrate the potential of camizestrant to become the backbone ET, with high combinability in vivo with inhibitors of CDK4/6, mTOR and AKT. These combinations demonstrate the opportunity to impact care of patients with early and metastatic ER+BC, delivering benefit to broad patient populations including those with ESR1wt or ESR1m tumors, independent of PI3K/AKT/PTEN pathway mutation status, and in patients with both CDK4/6i sensitive and resistant tumors.
- everolimus / Generic mfg.
Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207 (Hall 3) - Oct 10, 2022 - Abstract #SABCS2022SABCS_152;
P3
Among premenopausal patients there was a benefit in IDFS and OS that is hypothesis generating. Future translational studies will evaluate potential predictors of everolimus benefit and drug toxicity.
- Ibrance (palbociclib) / Pfizer
Real-world time-to-treatment discontinuation in hormone-receptor-positive metastatic breast cancer patients following CDK4/6 inhibitor treatment, based on observational data collected through patient-partnered research (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_781;
PRD helps develop hypotheses about patient response to treatment following CDK4/6 that can be further evaluated in larger, more diverse observational studies and clinical trials. Table 1.
- | everolimus / Generic mfg.
Preclinical, Journal: Baicalein activates 5' adenosine monophosphate-activated protein kinase, inhibits the mammalian target of rapamycin, and exhibits antiproliferative effects in pancreatic neuroendocrine tumors in vitro and in vivo. (Pubmed Central) - Oct 9, 2022
Table 1. Baicalein exhibits antiproliferative effects against pancreatic neuroendocrine tumor cell lines at doses ≥5 μM and demonstrates synergy.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_687;
Conclusions In this real-world experience, L+E showed substantial clinical activity in pre-treated mRCC patients, even after disease progression with IO combination. L+E combination is well tolerated with appropriate dose adjustment of lenvatinib.
- ||| cyclosporin A microemulsion / Generic mfg., everolimus / Generic mfg., sirolimus / Generic mfg.
Trial completion: Stability of Tacrolimus, Cyclosporine A, Everolimus and Sirolimus in Whole Blood Patient Samples (clinicaltrials.gov) - Oct 7, 2022
P=N/A, N=46, Completed, Sponsor: Thermo Fisher Scientific Oy
L+E combination is well tolerated with appropriate dose adjustment of lenvatinib. Recruiting --> Completed
- | Fycompa (perampanel) / Eisai, Diacomit (stiripentol) / Biocodex, Meiji Seika, Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Journal: Stability Indicating Methods for Determination of Third Generation Antiepileptic Drugs and Their Related Substances. (Pubmed Central) - Oct 7, 2022
A number of these antiepileptic drugs were found to have had a small number of studies related to their stability and for the detection of impurities. The presentation of the current level of research on third generation antiepileptic drugs highlights the need for new stability and safety studies that are necessary to develop new pharmaceutical products containing these drugs.
- || Ibrance (palbociclib) / Pfizer
Clinical data, Journal, Real-world evidence: Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population. (Pubmed Central) - Oct 6, 2022
The presentation of the current level of research on third generation antiepileptic drugs highlights the need for new stability and safety studies that are necessary to develop new pharmaceutical products containing these drugs. Various palbociclib-based regimens have promising efficacy in ER+ metastatic breast cancer in real-world settings, even in patients who had been pre-treated with everolimus.
- ||||| giredestrant (GDC-9545) / Roche
Enrollment change, Metastases: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) (clinicaltrials.gov) - Oct 6, 2022
P3, N=320, Recruiting, Sponsor: Genentech, Inc.
Various palbociclib-based regimens have promising efficacy in ER+ metastatic breast cancer in real-world settings, even in patients who had been pre-treated with everolimus. N=224 --> 320
- || Clinical, Journal: COVID-19 associated with disseminated histoplasmosis in a kidney transplant patient. (Pubmed Central) - Oct 5, 2022
In addition, plasma therapy was administered, and the immunosuppressive regimen was adjusted (everolimus was interrupted, mycophenolate mofetil reduced, and meprednisone increased). Finally, the patient's progress was favorable and was discharged after five days on oral itraconazole treatment for histoplasmosis.
- | REGEN-COV (casirivimab/imdevimab) / Regeneron, Roche
Journal: Case Report of COVID-19 Infection After Kidney Transplant Treated With Casirivimab-Imdevimab and Mycophenolate Mofetil Changed to Everolimus. (Pubmed Central) - Oct 5, 2022
It is suggested that casirivimab-imdevimab can prevent COVID-19 from becoming severe and can be administered without worsening renal function. In addition, everolimus may have inhibited the spread of the virus and prevented it from replicating.
- | everolimus / Generic mfg.
Journal: Everolimus Use in Lung Transplant Recipients. (Pubmed Central) - Oct 5, 2022
In addition, everolimus may have inhibited the spread of the virus and prevented it from replicating. After lung transplant, everolimus can be a safe alternative for immunosuppression with acceptable adverse effects.
- | everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
Journal: Hepatic Angiosarcoma Post-Renal Transplantation: A Case Report. (Pubmed Central) - Oct 5, 2022
After lung transplant, everolimus can be a safe alternative for immunosuppression with acceptable adverse effects. Various post-transplant malignancies are not uncommon after transplantation, warranting periodic screenings for any symptoms in these patients.
- | everolimus / Generic mfg.
Journal: Recurrent Cytomegalovirus Infection Controlled by the Introduction of Everolimus in a Simultaneous Pancreas-Kidney Transplantation Recipient: A Case Report. (Pubmed Central) - Oct 5, 2022
This resulted in a continuously negative CMV antigenemia test and a stable general condition. Understanding the characteristics of various immunosuppressive agents and appropriately controlling and managing infectious diseases is crucial for the good postoperative management of patients with SPK.
- | cyclosporin A microemulsion / Generic mfg., everolimus / Generic mfg., sirolimus / Generic mfg.
Journal: Interlaboratory comparison study of immunosuppressant analysis using a fully automated LC-MS/MS system. (Pubmed Central) - Oct 5, 2022
Understanding the characteristics of various immunosuppressive agents and appropriately controlling and managing infectious diseases is crucial for the good postoperative management of patients with SPK. The outcome of this study demonstrates a new level of result harmonization for LC-MS/MS based immunosuppressant analysis with a commercially available fully automated platform for routine clinical application.
- | everolimus / Generic mfg.
Preclinical, Journal: Molecular pathways enhance drug response prediction using transfer learning from cell lines to tumors and patient-derived xenografts. (Pubmed Central) - Oct 5, 2022
Using feature importance, we highlight the association between ER-Golgi trafficking pathway in everolimus sensitivity within breast cancer patients and the role of class II histone deacetylases and interlukine-12 in response to drugs for triple-negative breast cancer. Pathway information support transfer of drug response prediction models from cell lines to tumors and can provide biological interpretation underlying the predictions, serving as a steppingstone towards usage in clinical setting.
- | everolimus / Generic mfg.
Journal: Spontaneous Hepatitis C Virus Clearance in a Liver Transplant Recipient After Conversion From Tacrolimus to Everolimus. (Pubmed Central) - Oct 5, 2022
Pathway information support transfer of drug response prediction models from cell lines to tumors and can provide biological interpretation underlying the predictions, serving as a steppingstone towards usage in clinical setting. No abstract available
- || everolimus / Generic mfg.
Clinical, P2 data, Journal: A Randomized Multi-Institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. (Pubmed Central) - Oct 5, 2022
No abstract available p16-negative and TP53mut patients may benefit from adjuvant treatment with everolimus.
- Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Spikevax (elasomeran) / Moderna
Immunogenicity of the AstraZeneca, Moderna, and Pfizer COVID-19 vaccines in a South Australian cohort of immunocompromised liver transplant recipients () - Oct 4, 2022 - Abstract #AGW2022AGW_373;
A third dose improves the immunogenicity of the COVID-19 vaccines in healthy controls as well as in LT recipients. Of note, those receiving double or triple immunosuppressive regimens mount a lower response, potentially attributed to the use of azathioprine and mycophenolate, previously associated with lower seroconversion rates.
- || everolimus / Generic mfg.
PK/PD data, Journal: Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer. (Pubmed Central) - Oct 4, 2022
Based on our data, trough concentrations in the range of 10-20 ng/ml may be associated with prolonged progression-free survival. Thus, determining the blood concentration of everolimus and subsequent dose adjustments will potentially reduce side effects and enhance the therapeutic effect in Japanese patients with advanced breast cancer.
- || Clinical, Journal: An Italian multicentre distributed data research network to study the use, effectiveness, and safety of immunosuppressive drugs in transplant patients: Framework and perspectives of the CESIT project. (Pubmed Central) - Oct 4, 2022
Although the triple therapy in terms of CNI + antimet/mTOR + steroids was widely dispensed for all settings (63.7% for kidney, 33.5% for liver, 53.3% for heart, and 63.7% for lung), differences in the active agents involved were detected. The CESIT network represents a great opportunity to study several aspects related to the use, safety, and effectiveness of post-transplant maintenance immunosuppressive therapy in real practice.
- | cyclosporin A microemulsion / Generic mfg., everolimus / Generic mfg., sirolimus / Generic mfg.
Journal: Application of a Fully Automated Dried Blood Spot Method for Therapeutic Drug Monitoring of Immunosuppressants. (Pubmed Central) - Oct 4, 2022
After correction, both analytical and clinical acceptance criteria were met for all analytes. Automated DBS analysis shows great potential for routine therapeutic drug monitoring of immunosuppressants, avoiding any manual sample handling.
- | Ibrance (palbociclib) / Pfizer, Mekinist (trametinib) / Novartis, BeiGene, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
Trial primary completion date, Combination therapy, Metastases: NCI-2018-01218: Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation (clinicaltrials.gov) - Oct 4, 2022
P1, N=120, Recruiting, Sponsor: M.D. Anderson Cancer Center
Automated DBS analysis shows great potential for routine therapeutic drug monitoring of immunosuppressants, avoiding any manual sample handling. Trial primary completion date: Oct 2022 --> Oct 2023
- |||||| dordaviprone (ONC201) / Chimerix
Enrollment open: BIOMEDE 2: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 (clinicaltrials.gov) - Oct 3, 2022
P3, N=368, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Trial primary completion date: Oct 2022 --> Oct 2023 Not yet recruiting --> Recruiting
- dexamethasone / Generic mfg., everolimus / Generic mfg.
Ectopic ACTH syndrome in lung carcinoids – a case series () - Oct 1, 2022 - Abstract #ENEA2022ENEA_226;
The remaining patients are disease free (follow up range 24-168 months). In this work we will review clinical features at presentation, strains in tumour location and response to therapy.
- || Edsivo (celiprolol) / Acer Therap, Invirase (saquinavir) / Roche, Crixivan (indinavir sulfate) / Merck (MSD)
Review, Journal: Phytochemicals That Interfere With Drug Metabolism and Transport, Modifying Plasma Concentration in Humans and Animals. (Pubmed Central) - Sep 29, 2022
Interactions between Pchs and drugs affect the gene expression and enzymatic activity of CYP3A and P-gp transporter, which has an impact on their bioavailability; such that co-administration of drugs with food, beverages and food supplements can cause a subtherapeutic effect or overdose. Therefore, it is important for the clinician to consider these interactions to obtain a better therapeutic effect.
- || Review, Journal: Studying molecular signaling in major angiogenic diseases. (Pubmed Central) - Sep 29, 2022
In clinical therapeutics, target therapy focusing on discovery of novel anti-angiogenic agents like bevacizumab, cetuximab, sunitinib, imatinib, lenvatinib, thalidomide, everolimus etc., to block or inhibit the angiogenesis pathway is well explored in recent times. In this review, we will discuss about the molecular signaling pathways involved in major angiogenic diseases in detail.
- | remdesivir / Generic mfg.
Journal: Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient. (Pubmed Central) - Sep 29, 2022
There was no toxicity due to immunosuppressive agents during hospitalization. This case report indicated that remdesivir might interact with cytochrome P450 3A4 substrates, such as tacrolimus and everolimus, and elevate their blood concentrations under high inflammatory conditions.
- | everolimus / Generic mfg.
Observational data, Journal: Five-year Outcomes in Liver Transplant Patients Receiving Everolimus with or without a Calcineurin Inhibitor: Results from the CERTITUDE Study. (Pubmed Central) - Sep 29, 2022
This case report indicated that remdesivir might interact with cytochrome P450 3A4 substrates, such as tacrolimus and everolimus, and elevate their blood concentrations under high inflammatory conditions. The CERTITUDE study demonstrated that EVR- and TAC-based regimens have comparable efficacy, safety and tolerability up to 5 years post-LTx.
- || Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Retrospective data, Review, Journal: Systemic therapies for metastatic renal cell carcinoma in the second-line setting: A systematic review and network meta-analysis. (Pubmed Central) - Sep 28, 2022
When comprehensively evaluated the efficacy and safety of included treatment options, lenvatinib plus everolimus, cabozantinb, and nivolumab were associated with better survival benefits and lower risk of AEs. Future studies should focus on the direct comparison of different second-line treatment in real-world populations.
- Combined pharmacological and genetic screening to identify dependencies and combinations in ACVR1-mutant diffuse midline glioma (Ballroom A) - Sep 28, 2022 - Abstract #SNO2022SNO_1378;
Recently we reported that combinatorial treatment of ACVR1-mutant DIPG cells with vandetanib (RTK inhibitor) and everolimus (mTOR/ABC transporter inhibitor) was synergistic both in vitro and in vivo and was shown to be a feasible combination to trial clinically in this setting...Using a panel of 13 patient-derived ACVR1-mutant models (and 6 wild-type controls), we identified synergy between multiple chemotypes of ALK2i (M4K2009/LDN-214117) and PI3K/mTOR (AZD8055/everolimus) and MEK inhibitors (trametinib), reflecting the common co-segregation of PIK3CA/PIK3R1 alterations in these tumours...Additional hits include the serine/threonine kinase PKMYT1, a negative regulator of the G2/M checkpoint via a functionally redundant phosphorylation of CDK1/CCNB1 alongside WEE1; confirmatory drug assays with the WEE1 inhibitor AZD1775 resulted in a synergistic interaction with ALK2i in ACVR1-mutant cells...Preliminary pathway enrichment analysis (MAGeCKFlute) identified ALK2i-specific vulnerabilities involving TGFB1/SMAD signalling and histone deacetylation. These data highlight functionally rational and novel combinatorial possibilities for children with ACVR1-mutant DMG, with systematic preclinical assessment required for prioritisation for the clinic.
- Kisqali (ribociclib) / Novartis
A phase 0/1 trigger trial of Ribociclib plus Everolimus in recurrent high-grade glioma (West/Central Hall) - Sep 28, 2022 - Abstract #SNO2022SNO_487;
Everolimus exhibits limited penetration into human glioma tissue. Our study supports further development of ribociclib, but not everolimus, for the treatment of glioma patients.
- Kisqali (ribociclib) / Novartis
A phase 0/1 trigger trial of Ribociclib plus Everolimus in recurrent high-grade glioma (West/Central Hall) - Sep 28, 2022 - Abstract #SNO2022SNO_223;
Everolimus exhibits limited penetration into human glioma tissue. Our study supports further development of ribociclib, but not everolimus, for the treatment of glioma patients.
- | Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Metastases: NCI-2018-01284: A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Sep 26, 2022
P2, N=87, Recruiting, Sponsor: M.D. Anderson Cancer Center
Our study supports further development of ribociclib, but not everolimus, for the treatment of glioma patients. Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
- | Piqray (alpelisib) / Novartis, Mekinist (trametinib) / Novartis
Preclinical, Journal: Co-Targeting MAP Kinase and Pi3K-Akt-mTOR Pathways in Meningioma: Preclinical Study of Alpelisib and Trametinib. (Pubmed Central) - Sep 25, 2022
Combined treatment with alpelisib plus trametinib reversed the AKT activation induced by trametinib and induced an additive inhibitory effect irrespective of the cell lines or tumor features. Co-targeting pathways seems promising and may be considered particularly for aggressive meningioma.
- || everolimus / Generic mfg.
Biomarker, Clinical data, Journal: Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes. (Pubmed Central) - Sep 25, 2022
P2
Our study suggested the evidence that circulating cells might be surrogate biomarkers of angiogenesis activity in patients treated with everolimus and their baseline levels can be correlated with survival. However, further studies are now needed to validate the role of these cells as surrogate markers for the selection of patients to be candidates for antiangiogenic treatments.
- | carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Biomarker, Journal, Tumor microenvironment, IO biomarker: Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study. (Pubmed Central) - Sep 25, 2022
The combination of everolimus and chemotherapy in HNSCC was safe and achieved major tumor responses. This strategy favorably impacts the TME and might be combined with immunotherapeutic agents.
- || sapanisertib (CB-228) / Calithera, serabelisib (MLN1117) / Takeda, Petra Pharma, Faeth Therap
P2 data, Journal: Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy. (Pubmed Central) - Sep 24, 2022
Sapanisertib with or without TAK-117 was less tolerable and did not improve efficacy vs. everolimus in patients with advanced ccRCC who had relapsed after or were refractory to VEGF-targeted therapies. Dual mTORC1/2 inhibition may not be an effective therapeutic approach for these patients.
- | Torisel (temsirolimus) / Pfizer
Journal: Can We Use mTOR Inhibitors for COVID-19 Therapy? (Pubmed Central) - Sep 24, 2022
The officially accepted mTOR inhibitors that have undergone clinical testing are sirolimus, everolimus, temsirolimus, and tacrolimus. Thus, further studies on mTOR inhibitors for SARS-CoV-2 infection or COVID-19 therapy are well merited.
- || everolimus / Generic mfg.
Retrospective data, Review, Journal: Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data. (Pubmed Central) - Sep 24, 2022
Per 100 mg increase in total SSA dosage, the odds ratios for obtaining radiological disease control was 1.42 (1.11 to 1.81, P = 0.005) and 1.44 (1.00 to 2.08, P = 0.05) for patients treated with SSA as monodrug therapy vs SSA in combination with everolimus, respectively...Yet, the SSA treatment was well tolerated, and beneficial effect cannot be disqualified. A prospective trial without bias from inconsistent study designs is warranted to assess SSA therapy for well-defined meningioma subgroups.
- | imatinib / Generic mfg., everolimus / Generic mfg.
Preclinical, Journal: Effects of Imatinib Combined With Everolimus on Mouse Pituitary Tumor Cell AtT-20. (Pubmed Central) - Sep 24, 2022
Imatinib combined with everolimus can affect the AtT-20 cell cycle through the signaling pathway of the phosphatidylin-ositol-3-kinase (PI3K)/Akt/ protein kinase A (PKA) system and can inhibit cell proliferation and induce cell apoptosis. Therefore, Imatinib and everolimus may be an effective combination of candidates for drugs for mouse pituitary tumor.
- ||||| everolimus / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Highlight Article: Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial https://t.co/4R3YxKQq4O @montypal @docjavip @DrDanielHeng (Twitter) - Sep 23, 2022